- /
- Supported exchanges /
- NASDAQ /
- TIL.NASDAQ
Instil Bio Inc. (TIL NASDAQ) stock market data APIs
Instil Bio Inc. Financial Data Overview
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Instil Bio Inc. data using free add-ons & libraries
Get Instil Bio Inc. Fundamental Data
Instil Bio Inc. Fundamental data includes:
- Net Revenue: 0
- EBITDA: -66 022 000
- Earnings Per Share: -11
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-11
- EPS/Forecast: -2.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Instil Bio Inc. News
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Investors looking for stocks that can provide dramatic gains found what they were looking for with a pair of cancer drug developers. From the end of 2023 through the closing bell on Sept. 23, shares o...
Here's Why Everyone's Talking About Summit Therapeutics
September has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious c...
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, thera...
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, thera...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.